CRISPR Beyond Gene Editing: How the Technology Is Evolving into a Universal Biological Tool

# CRISPR Beyond Gene Editing: How the Technology Is Evolving into a Universal Biological Tool

You've heard of CRISPR as a gene editor — the molecular scissors that can cut DNA at a precise location. That description is accurate, but it's also increasingly incomplete. The CRISPR toolkit has expanded so dramatically over the past decade that calling it a "gene editor" is a bit like calling the internet a "fax machine replacement." The original function is still there, but it now does vastly more.

Think about it this way: Cas9, the protein that made CRISPR famous, is just one member of a growing family of CRISPR-associated proteins, each with different capabilities. Researchers have now built tools that can make a single-letter change in DNA without cutting both strands, rewrite DNA without any cut at all, control gene expression without touching the sequence, and diagnose infections in the field in under an hour. CRISPR has evolved from scissors into something closer to a universal programmable interface for biological information.

## But what's wrong with just cutting DNA?

The original CRISPR-Cas9 system works by creating a double-strand break — cutting completely through both strands of the DNA helix. The cell then repairs the break, and if you've delivered a template for the repair, it will sometimes incorporate changes you wanted. This approach is powerful for knocking out a gene entirely. For precision edits — say, correcting a single-letter mutation that causes sickle cell disease — it's less ideal. Double-strand breaks are messy. The repair machinery doesn't always do what you want.

**Base editing**, developed in David Liu's lab at the Broad Institute, solved this elegantly. Instead of cutting, a base editor fuses a deactivated Cas9 (which can still find and bind to a target sequence, but can't cut) to a chemical enzyme that directly converts one DNA letter to another. Adenine base editors convert A•T base pairs to G•C. Cytosine base editors convert C•G to T•A. No double-strand break, no template required, just a precise chemical conversion at a specified location.

This matters enormously for medicine. An estimated 58 percent of the roughly 75,000 known pathogenic single-nucleotide variants in the human genome are point mutations — single letter changes — of exactly the type base editing can correct.

> 🔬 **Quick experiment:** Think of it like this — if the genome is a book, classical CRISPR rips out a page. Base editing changes a single letter on that page. Prime editing can rewrite an entire sentence.

## So what can prime editing do that base editing can't?

**Prime editing** goes further. Developed in 2019 (also in Liu's lab), it uses a modified Cas9 fused to a reverse transcriptase — an enzyme borrowed from retroviruses that can write RNA sequences into DNA. A specially designed guide RNA carries both the targeting sequence and the desired edit as a template. The result is a system that can make all twelve possible point mutations, small insertions, and small deletions without double-strand breaks and without a separate DNA template. Think of it as a word processor for the genome — find, delete, replace.

The practical scope of what prime editing can fix has expanded rapidly. Early clinical-stage programs are targeting beta-thalassemia, chronic granulomatous disease, and several forms of inherited deafness.

## What about controlling genes without changing them?

Here's the weird part: sometimes you don't want to change the DNA sequence at all. You just want to turn a gene up or down. This is where **CRISPRi** (interference) and **CRISPRa** (activation) come in.

Both systems use a catalytically dead Cas9 — dCas9 — that can still be guided to a specific genomic location but cannot cut. Fuse it to a repressor domain and you get CRISPRi, which can silence a target gene. Fuse it to an activator domain and you get CRISPRa, which can amplify gene expression. No permanent edit to the sequence, just programmable control of the regulatory machinery.

The applications extend into neuroscience, cancer biology, and any research area where you want to understand what a specific gene does without permanently altering a cell line. These tools have become essential in large-scale functional genomics screens — the biological equivalent of checking what happens when you flip each switch in a complex circuit board, one at a time.

**Epigenome editing** takes this further. Rather than changing the DNA sequence or even gene expression directly, these tools target the chemical modifications on histones — the protein spools around which DNA is wrapped — that influence which genes are accessible to the transcription machinery. Early epigenome editing tools can now silence genes for months in mouse models without altering the underlying DNA sequence at all.

## CRISPR as a diagnostic tool — SHERLOCK and DETECTR

One of the most surprising branches of the CRISPR toolkit is diagnostic. Researchers discovered that certain Cas proteins — particularly Cas12 and Cas13 — have a property called *collateral cleavage*: once activated by their target, they start cutting any nearby single-stranded nucleic acid indiscriminately. This looks like a bug, but it's actually a feature.

**SHERLOCK** (Specific High Sensitivity Enzymatic Reporter UnLOCKing) and **DETECTR** (DNA Endonuclease-Targeted CRISPR Trans Reporter) exploit this property. Design a guide RNA that targets a specific pathogen sequence — say, a dengue virus RNA or a specific bacterial gene conferring antibiotic resistance — and include a reporter molecule that produces a fluorescent signal when cleaved. If the target is present, Cas13 binds to it, activates, and cuts the reporter. You see a signal.

During the COVID-19 pandemic, SHERLOCK-based detection assays were developed within weeks of the SARS-CoV-2 sequence becoming available. Some versions were designed to work on paper strips at room temperature. The vision: a diagnostic platform as cheap and portable as a pregnancy test that can detect any pathogen you can program a guide RNA for.

## Where is the technology headed?

The field is moving toward *in vivo* delivery — using CRISPR tools not in a dish or in cells removed from a patient, but directly inside a living organism. The primary challenge is delivery: getting the editing machinery into the right tissue without triggering immune responses or off-target effects. Lipid nanoparticles have emerged as a promising vehicle, particularly for liver-targeted applications (given that the liver filters blood efficiently). The first CRISPR therapy approved by the FDA — for sickle cell disease and beta-thalassemia — used an ex vivo approach, editing patients' own stem cells outside the body before reinfusing them. Fully in vivo approaches are still in early clinical stages.

The next decade will likely see base and prime editing enter clinical practice for a range of monogenic diseases, epigenome editing mature as a research tool, and CRISPR diagnostics expand into point-of-care settings in resource-limited environments. The molecular scissors have become something much larger. Science, it turns out, had a much better use for them than anyone initially imagined.

CRISPR Beyond Gene Editing: How the Technology Is Evolving into a Universal Biological Tool

// COMMENTS

ON THIS PAGE